TOUCAN: A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin.
(2016)
Journal Article
Jones, R. J., Crabb, S. J., Chester, J. D., Elliott, T., Huddart, R. A., Birtle, A. J., Evans, L., Lester, J. F., Huang, C., Casbard, A. C., Madden, T.-A., & Griffiths, G. (2016). TOUCAN: A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin. Journal of Clinical Oncology, 34(2_suppl), 448-448. https://doi.org/10.1200/jco.2016.34.2_suppl.448
Background: Whilst cisplatin combination therapy remains the standard of care for patients with advanced urothelial cancers, many patients are unsuitable for cisplatin and go on to receive carboplatin combination therapy. Although responses are frequ... Read More about TOUCAN: A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin..